221 related articles for article (PubMed ID: 25888793)
1. Antisense oligonucleotide-mediated exon skipping of CHRNA1 pre-mRNA as potential therapy for Congenital Myasthenic Syndromes.
Tei S; Ishii HT; Mitsuhashi H; Ishiura S
Biochem Biophys Res Commun; 2015 Jun; 461(3):481-6. PubMed ID: 25888793
[TBL] [Abstract][Full Text] [Related]
2. HnRNP L and hnRNP LL antagonistically modulate PTB-mediated splicing suppression of CHRNA1 pre-mRNA.
Rahman MA; Masuda A; Ohe K; Ito M; Hutchinson DO; Mayeda A; Engel AG; Ohno K
Sci Rep; 2013 Oct; 3():2931. PubMed ID: 24121633
[TBL] [Abstract][Full Text] [Related]
3. Splicing regulation and dysregulation of cholinergic genes expressed at the neuromuscular junction.
Ohno K; Rahman MA; Nazim M; Nasrin F; Lin Y; Takeda JI; Masuda A
J Neurochem; 2017 Aug; 142 Suppl 2():64-72. PubMed ID: 28072465
[TBL] [Abstract][Full Text] [Related]
4. hnRNP H enhances skipping of a nonfunctional exon P3A in CHRNA1 and a mutation disrupting its binding causes congenital myasthenic syndrome.
Masuda A; Shen XM; Ito M; Matsuura T; Engel AG; Ohno K
Hum Mol Genet; 2008 Dec; 17(24):4022-35. PubMed ID: 18806275
[TBL] [Abstract][Full Text] [Related]
5. Tannic acid facilitates expression of the polypyrimidine tract binding protein and alleviates deleterious inclusion of CHRNA1 exon P3A due to an hnRNP H-disrupting mutation in congenital myasthenic syndrome.
Bian Y; Masuda A; Matsuura T; Ito M; Okushin K; Engel AG; Ohno K
Hum Mol Genet; 2009 Apr; 18(7):1229-37. PubMed ID: 19147685
[TBL] [Abstract][Full Text] [Related]
6. Exonic sequences provide better targets for antisense oligonucleotides than splice site sequences in the modulation of Duchenne muscular dystrophy splicing.
Aartsma-Rus A; Houlleberghs H; van Deutekom JC; van Ommen GJ; 't Hoen PA
Oligonucleotides; 2010 Apr; 20(2):69-77. PubMed ID: 20377429
[TBL] [Abstract][Full Text] [Related]
7. Correction of a Cystic Fibrosis Splicing Mutation by Antisense Oligonucleotides.
Igreja S; Clarke LA; Botelho HM; Marques L; Amaral MD
Hum Mutat; 2016 Feb; 37(2):209-15. PubMed ID: 26553470
[TBL] [Abstract][Full Text] [Related]
8. Overview on AON design.
Aartsma-Rus A
Methods Mol Biol; 2012; 867():117-29. PubMed ID: 22454058
[TBL] [Abstract][Full Text] [Related]
9. The therapeutic potential of antisense-mediated exon skipping.
van Ommen GJ; van Deutekom J; Aartsma-Rus A
Curr Opin Mol Ther; 2008 Apr; 10(2):140-9. PubMed ID: 18386226
[TBL] [Abstract][Full Text] [Related]
10. Splicing abnormalities in congenital myasthenic syndromes.
Ohno K; Engel AG
Acta Myol; 2005 Oct; 24(2):50-4. PubMed ID: 16550914
[TBL] [Abstract][Full Text] [Related]
11. New developments in exon skipping and splice modulation therapies for neuromuscular diseases.
Touznik A; Lee JJ; Yokota T
Expert Opin Biol Ther; 2014 Jun; 14(6):809-19. PubMed ID: 24620745
[TBL] [Abstract][Full Text] [Related]
12. Functional analysis of 114 exon-internal AONs for targeted DMD exon skipping: indication for steric hindrance of SR protein binding sites.
Aartsma-Rus A; De Winter CL; Janson AA; Kaman WE; Van Ommen GJ; Den Dunnen JT; Van Deutekom JC
Oligonucleotides; 2005 Dec; 15(4):284-97. PubMed ID: 16396622
[TBL] [Abstract][Full Text] [Related]
13. DMD pseudoexon mutations: splicing efficiency, phenotype, and potential therapy.
Gurvich OL; Tuohy TM; Howard MT; Finkel RS; Medne L; Anderson CB; Weiss RB; Wilton SD; Flanigan KM
Ann Neurol; 2008 Jan; 63(1):81-9. PubMed ID: 18059005
[TBL] [Abstract][Full Text] [Related]
14. Target selection for antisense oligonucleotide induced exon skipping in the dystrophin gene.
Errington SJ; Mann CJ; Fletcher S; Wilton SD
J Gene Med; 2003 Jun; 5(6):518-27. PubMed ID: 12797117
[TBL] [Abstract][Full Text] [Related]
15. RNA Secondary Structure-Based Design of Antisense Peptide Nucleic Acids for Modulating Disease-Associated Aberrant Tau Pre-mRNA Alternative Splicing.
Ong AAL; Tan J; Bhadra M; Dezanet C; Patil KM; Chong MS; Kierzek R; Decout JL; Roca X; Chen G
Molecules; 2019 Aug; 24(16):. PubMed ID: 31434312
[TBL] [Abstract][Full Text] [Related]
16. Personalized Development of Antisense Oligonucleotides for Exon Skipping Restores Type XVII Collagen Expression in Junctional Epidermolysis Bullosa.
Ablinger M; Lettner T; Friedl N; Potocki H; Palmetzhofer T; Koller U; Illmer J; Liemberger B; Hainzl S; Klausegger A; Reisenberger M; Lambert J; Van Gele M; Desmet E; Van Maelsaeke E; Wimmer M; Zauner R; Bauer JW; Wally V
Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33805154
[TBL] [Abstract][Full Text] [Related]
17. Design of Bifunctional Antisense Oligonucleotides for Exon Inclusion.
Zhou H
Methods Mol Biol; 2022; 2434():53-62. PubMed ID: 35213009
[TBL] [Abstract][Full Text] [Related]
18. Guidelines for antisense oligonucleotide design and insight into splice-modulating mechanisms.
Aartsma-Rus A; van Vliet L; Hirschi M; Janson AA; Heemskerk H; de Winter CL; de Kimpe S; van Deutekom JC; 't Hoen PA; van Ommen GJ
Mol Ther; 2009 Mar; 17(3):548-53. PubMed ID: 18813282
[TBL] [Abstract][Full Text] [Related]
19. Characterization of hprt splicing mutations induced by the ultimate carcinogenic metabolite of benzo[a]pyrene in Chinese hamster V-79 cells.
Hennig EE; Conney AH; Wei SJ
Cancer Res; 1995 Apr; 55(7):1550-8. PubMed ID: 7882364
[TBL] [Abstract][Full Text] [Related]
20. Nuclear antisense effects in cyclophilin A pre-mRNA splicing by oligonucleotides: a comparison of tricyclo-DNA with LNA.
Ittig D; Liu S; Renneberg D; Schümperli D; Leumann CJ
Nucleic Acids Res; 2004; 32(1):346-53. PubMed ID: 14726483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
